Abivax (ABVX) Competitors

In the previous week, Abivax had 21 more articles in the media than Moderna. MarketBeat recorded 37 mentions for Abivax and 16 mentions for Moderna. Abivax's average media sentiment score of 0.57 beat Moderna's score of 0.55 indicating that Abivax is being referred to more favorably in the news media.

Moderna has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Abivax has lower revenue, but higher earnings than Moderna. Abivax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Moderna currently has a consensus target price of $37.13, suggesting a potential downside of 53.44%. Abivax has a consensus target price of $146.00, suggesting a potential upside of 0.93%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than Moderna.

Abivax has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Abivax's return on equity.

In the previous week, Abivax had 34 more articles in the media than BioNTech. MarketBeat recorded 37 mentions for Abivax and 3 mentions for BioNTech. BioNTech's average media sentiment score of 0.67 beat Abivax's score of 0.57 indicating that BioNTech is being referred to more favorably in the media.

BioNTech presently has a consensus price target of $129.56, suggesting a potential upside of 32.83%. Abivax has a consensus price target of $146.00, suggesting a potential upside of 0.93%. Given BioNTech's higher probable upside, equities analysts plainly believe BioNTech is more favorable than Abivax.

15.5% of BioNTech shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Abivax has lower revenue, but higher earnings than BioNTech. Abivax is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Abivax has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Abivax's return on equity.

BioNTech has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Abivax has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Abivax has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Abivax's return on equity.

Abivax presently has a consensus price target of $146.00, indicating a potential upside of 0.93%. Roivant Sciences has a consensus price target of $33.59, indicating a potential downside of 4.38%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than Roivant Sciences.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Abivax had 20 more articles in the media than Roivant Sciences. MarketBeat recorded 37 mentions for Abivax and 17 mentions for Roivant Sciences. Abivax's average media sentiment score of 0.57 beat Roivant Sciences' score of 0.56 indicating that Abivax is being referred to more favorably in the media.

Roivant Sciences has higher revenue and earnings than Abivax. Roivant Sciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Abivax has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Abivax has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Abivax has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Abivax's return on equity of -99.02% beat Insmed's return on equity.

Abivax currently has a consensus price target of $146.00, suggesting a potential upside of 0.93%. Insmed has a consensus price target of $211.86, suggesting a potential upside of 89.84%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Abivax.

In the previous week, Abivax had 30 more articles in the media than Insmed. MarketBeat recorded 37 mentions for Abivax and 7 mentions for Insmed. Insmed's average media sentiment score of 1.42 beat Abivax's score of 0.57 indicating that Insmed is being referred to more favorably in the news media.

Abivax has higher earnings, but lower revenue than Insmed. Abivax is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.